Moxifloxacin Teva (Moxifloxacin Hydrochloride)

Moxifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This blockade prevents bacterial cell division, leading to bacterial death and resolution of the infection.

The dose of Moxifloxacin Teva is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. No fixed regimen is provided here.

Safety data for Moxifloxacin during pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and better activity in respiratory infections compared with older fluoroquinolones such as ciprofloxacin. It also has a longer half‑life, allowing once‑daily dosing, but shares class‑related safety considerations like QT prolongation and tendon toxicity.

The product must be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Use aseptic techniques when preparing the injection, and discard any solution that appears discolored or contains particles.

Moxifloxacin Teva is administered intravenously by a healthcare professional. The solution is typically diluted in an appropriate compatible IV fluid and infused over a prescribed period, usually 30‑60 minutes, under aseptic conditions.

Serious risks include tendon rupture, QT interval prolongation leading to potentially fatal arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and hepatic failure. Patients should be monitored closely for any signs of these events.

Moxifloxacin Teva should be avoided in patients with known hypersensitivity to fluoroquinolones, a history of tendon disorders related to fluoroquinolone use, uncontrolled QT prolongation, or those taking other medications that significantly prolong the QT interval. Caution is also advised in pregnant or breastfeeding women.